U.K. life sciences sector to maintain strong growth trajectory despite market normalization

The U.K. life sciences sector will maintain its strong growth trajectory, despite investment market normalization since the 2021 boom, according to CBRE in its recent report, Trends that transcend the U.S.–U.K. life sciences industry.

The life sciences real estate sector is boasting an impressive development pipeline in the United Kingdom, namely in the “golden triangle” locations — Cambridge, London and Oxford — which are earmarked for more than 10 million square feet (4 million square feet, 2.2 million square feet and 4 million square feet, respectively) of potential deliverable real estate in the next five years.

This activity follows substantial venture capital investment, which has more than doubled in the past five years. Notably, in 2021, 80 percent of the sector VC funding in the United Kingdom was allocated to the Cambridge, London and Oxford areas.

The report notes capability in next-generation therapies manufacturing is growing in t